# Letters

# Chronic hepatitis E: an important entity for clinicians to be aware of

We read with interest the recent article by Miller and colleagues<sup>1</sup> that highlighted a case of bilateral neuralgic amyotrophy in a patient who acquired hepatitis E from livestock. They provided a concise review of the epidemiology of hepatitis E and its acute clinical manifestations.

One important concept that we would like to highlight is that, although hepatitis E is predominantly an acute, self-limited infection with uncommon cases of liver failure, as reported by the authors, chronic hepatitis E infection can occur in patients who are immunosuppressed with substantial morbidity.<sup>2</sup>

Chronic hepatitis E was first reported in 2008 in transplant recipients; most cases have been reported in Europe, although a few have been reported in North America.<sup>3</sup> Although most common in transplant recipients, chronic hepatitis E has also been reported in patients requiring immunosuppression for rheumatological conditions<sup>2</sup> and in patients with hematological conditions.<sup>3</sup>

Diagnosis of chronic hepatitis E (assessed by the simultaneous assessment for anti-hepatitis E antibodies and hepatitis E RNA) is often under-recognized as many patients are asymptomatic, and the infection may only be recognized with abnormal results from liver tests. Chronic hepatitis E can lead to rapid progression of liver disease with the possibility of developing cirrhosis within 2 years.4 A history of direct farm exposure may be lacking as hepatitis E is predominately acquired through ingestion of undercooked pork products. Treatment of chronic hepatitis E is challenging; the current first-line therapy is reduction of immunosuppression (often a difficult prospect for transplant recipients and other patients on immunosuppression therapy) and oral ribavirin for a minimum of 3 months,5 with limited options for patients who do not respond to treatment.

Awareness of chronic hepatitis E is critical in the management of populations who are immunosuppressed and should be an important consideration on

the differential diagnosis with abnormal results from liver tests. Early identification, staging and treatment — coordinated by experts in hepatology and infectious disease — are important to reduce the risk of adverse outcomes for patients with chronic hepatitis E.

### Stephen E. Congly MD MSc

Transplant hepatologist, Divisions of Gastroenterology and Hepatology and Medical Transplant, Department of Medicine, University of Calgary, Calgary, Alta.

#### Michael D. Parkins MD MSc

Infectious diseases physician, Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, Alta.

# Karen E. Doucette MD MSc

Infectious diseases physician, Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alta.

Cite as: CMAJ 2022 September 26; 194:E1292. doi: 10.1503/cmaj.147045-l

## References

- Miller NJ, Hooper DR, Sharma A. Bilateral neuralgic amyotrophy in a patient with livestock-associated hepatitis E virus infection. CMAJ 2022;194:E495-9.
- Horvatits T, Schulze zur Wiesch J, Lütgehetmann M, et al. The clinical perspective on hepatitis E. Viruses 2019;11:617.
- Ma Z, de Man RA, Kamar N, et al. Chronic hepatitis E: advancing research and patient care. J Hepatol 2022 May 21 [Epub ahead of print]. doi: 10.1016/j.jhep.2022.05.006.
- Zhou X, de Man RA, de Knegt RJ, et al. Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Rev Med Virol 2013;23:295-304.
- Kar P, Karna R. A review of the diagnosis and management of hepatitis E. Curr Treat Options Infect Dis 2020;12:310-20.

**Competing interests:** None declared.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use) and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/